Peptides to Avoid: Which Ones Are Unsafe

Are Peptides Safe, and Which Ones to Avoid?

Any clinic can publish the list of what it sells. The more revealing document is the list of what it refuses to prescribe, and why. This guide is that list. It is a companion to what providers review before prescribing peptides Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. Here is the checklist they run from the other side of the screen: the conditions that change whether a peptide is safe, the medications that get cross-checked, and what gets escalated or declined.Read article , which covers the checklist a provider runs on an individual request. This one sits a level above, at the catalog. Before a single intake is reviewed, a peptide has to clear a threshold to be on offer at all. Three questions decide it: is there a pharmacy-grade source, is there a legitimate medical use, and does the benefit outweigh any documented risk. A no on any one is a decline. When you get a peptide through PeRx, it is prescribed by a licensed provider and compounded in a US-based, FDA-regulated 503A pharmacy, the same regulated pathway many everyday prescriptions go through.

Reason 1: No Pharmacy-Grade Source

The most common reason we decline a peptide is that there is no legitimate way to source it. PeRx only prescribes peptides a licensed compounding pharmacy will prepare against a patient-specific prescription. If the only supply is the gray market, there is nothing for us to prescribe, however interesting the molecule. This is where most of the peptides people ask us about fall out. Melanotan II, the injectable tanning peptide, has no FDA-approved or pharmacy-grade source in the United States. The same is true of the bodybuilding growth-hormone secretagogues sold as research chemicals. They live entirely on the gray market, which is exactly why we cannot offer them.

That market is real and large. Investigative reporting has described how wellness spas, multilevel marketers, and telehealth sites sell vials of "research grade" peptides labeled "not for human use," a label that lets a vendor move the material while disclaiming the obvious use. The problem is not the label. It is that with no pharmacy in the chain, nothing verifies what is in the vial. ProPublica reported that the manufacturing process can introduce impurities including bacteria and heavy metals, and that peptides are chemically unstable and can change composition if stored at the wrong temperature or handled roughly, which raises contamination risk or simply renders the product inert.

Bedell J. "An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs." ProPublica (2025): documents gray-market "research grade" peptides labeled "not for human use," and the risk of impurities including bacteria and heavy metals plus instability from improper handling. View study

A pharmacy-grade source is what closes that gap. A licensed pharmacy works from a verified active ingredient and issues a certificate of analysis confirming the vial’s identity, purity, and sterility. That document is the difference between a medication and a chemistry experiment, and it is exactly what a gray-market peptide cannot produce. Our guide on how to read a peptide COA Read nextHow to Read a Peptide COAA Certificate of Analysis is the lab report behind a peptide vial. Learn to read one line by line: identity, purity, net peptide content, sterility, and endotoxin. Then learn the red flags that separate a real prescription COA from a gray-market screenshot.Read article walks through what one actually shows. The short version: when a peptide has no pharmacy-grade source, declining it is not caution, it is the only responsible option.

Reason 2: No Legitimate Medical Use, Just Hype

The second reason has nothing to do with sourcing and everything to do with whether there is a real reason to use the peptide at all. A molecule can be sold on nothing but marketing. A vivid mechanism, a viral before-and-after, an influencer protocol: none of those is a medical indication. Melanotan II is instructive here too. It is marketed almost entirely on cosmetic appeal, a faster tan with less sun, which is not a problem a provider prescribes to solve. When a peptide is popular only because it is being marketed well, there is nothing for a provider to actually be treating or supporting, and we decline it.

It is worth being precise, because this is not the same as turning away anything new. Plenty of legitimate peptides are early in their human research and we are comfortable offering them, because there is a defensible clinical rationale and a definable job they do. The line is not how many trials a peptide has. It is whether the peptide answers a real need or simply rides a trend. For the basics of what peptide therapy is actually for, see what is peptide therapy Read nextWhat Is Peptide Therapy? Benefits, Evidence & Is It Worth ItThe honest version, not the marketing one: how peptides work, which ones actually have research behind them, what treatment and cost look like, and how to tell a legitimate provider from the gray market.Read article .

Reason 3: A Documented Safety Risk

The third reason applies even to peptides that can be sourced and have a plausible use. Sometimes the problem is that the known risk is real and the upside does not justify it. This is a different judgment from "we do not have much data yet." Here the concern is not silence in the literature, it is a documented signal of harm: peptides linked to serious adverse events, ones prone to contamination, or ones whose interactions make them genuinely hazardous. When the demonstrated downside is larger than any benefit we could honestly claim, we decline.

Bedell J. "An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs." ProPublica (2025): reports that subjects exposed to several injectable peptides experienced adverse events including death (causality not definitively established), and that injectable peptides carry immune-reaction risk up to anaphylaxis. View study

Regulators make a version of this same call. When the FDA evaluates substances nominated for compounding under Section 503A, it has placed some into a category specifically because significant safety risks were identified with their use. We are not the FDA, and the regulatory picture for peptides has been a shifting gray zone through 2025 and 2026. But the logic we borrow is simple: a documented safety risk that outweighs the benefit is a reason to keep a substance off the catalog, not a detail to gloss over.

U.S. Food & Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act": the agency has placed substances into a category because significant safety risks were identified with their use in compounding. View study

Melanotan II: What the Evidence Shows

Melanotan II is worth its own section because it fails all three tests at once, and because "melanotan side effects" is one of the questions people arrive with. It is a synthetic analog of alpha-melanocyte-stimulating hormone, marketed online as a tanning injection and sometimes a libido aid. It is not FDA-approved. There is no licensed pharmacy that will compound it against a prescription, so every vial for sale comes from the gray market, with all the identity and purity problems that implies. On sourcing alone, it is off the table for us.

The dermatology concern is the part that pushes it firmly into the third category. Because melanotan II drives pigment production in melanocytes, the same cells involved in skin cancer, clinicians have paid close attention to what it does to moles. A case report in the European Journal of Dermatology described new moles erupting and pre-existing moles darkening within 24 hours of a single injection. A separate report from Australian dermatologists flagged the unregulated use of melanotan II as a matter of public-health interest. A mole that suddenly appears, grows, or changes color is one of the warning signs clinicians screen for when they look for skin cancer, so a substance that provokes exactly those changes is not one a responsible provider hands out for a cosmetic tan.

Schulze F, Erdmann H, Hardkop LH, Anemüller W. "Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II." European Journal of Dermatology (2014): documents new naevi and darkening of existing naevi within 24 hours of a single melanotan II injection. View study

Adler NR, Dowling JP, Pan Y. "The unregulated use of melanotan-II is of public health interest to Australian dermatologists." Australasian Journal of Dermatology (2017): dermatologists flag unregulated melanotan II use as a public-health concern. View study

To be careful about what these reports do and do not show: they are case reports and clinical concern, not proof that melanotan II causes melanoma in a defined population. That level of certainty does not exist for a gray-market substance no one is running trials on, and the absence of that data is itself part of the problem. We do not need to prove the worst case to decline. A gray-market source, a purely cosmetic use, and a documented pattern of mole changes are already three independent reasons to leave it off the catalog.

What This Restraint Signals About Quality

Put the three reasons together and a pattern shows up. We decline peptides with no pharmacy-grade source, peptides sold on hype with no real medical use, and peptides whose documented risk outweighs any benefit we could honestly claim. Melanotan II lands in all three. Every one of those calls is a place where saying yes would have been easier and more profitable. We said no on purpose. That is the signal worth reading.

A useful test for any peptide service: ask what it will not prescribe, and why. If the answer is "we offer everything," that is not breadth, it is the absence of a standard. The clinics worth trusting are the ones that can name their lines and defend them. When you are ready to see the result of applying these standards, the peptides we do offer are what is left after the list above is removed. Each order ships fully reconstituted and ready to use, delivered overnight in refrigerated packaging, with nothing to mix on your end. What survived the filter is a short list: BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide , tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide , MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide , and a handful of others.

Peptides to Avoid: Common Questions